In addition, anti-PD-L1 therapy sensitized pancreatic cancer cells to antiangiogenic therapy and, conversely, antiangiogenic therapy improved anti-PD-L1 therapy [80]. This evidence concerns the gene CD274 and pancreatic neoplasm.